MX391735B - Anticuerpos que se enlazan al receptor del factor 1 estimulador de colonias (csf1r) y sus usos en el tratamiento de trastornos por cd16+ - Google Patents

Anticuerpos que se enlazan al receptor del factor 1 estimulador de colonias (csf1r) y sus usos en el tratamiento de trastornos por cd16+

Info

Publication number
MX391735B
MX391735B MX2016016664A MX2016016664A MX391735B MX 391735 B MX391735 B MX 391735B MX 2016016664 A MX2016016664 A MX 2016016664A MX 2016016664 A MX2016016664 A MX 2016016664A MX 391735 B MX391735 B MX 391735B
Authority
MX
Mexico
Prior art keywords
csf1r
antibodies
receptor
bind
stimulating factor
Prior art date
Application number
MX2016016664A
Other languages
English (en)
Spanish (es)
Other versions
MX2016016664A (es
Inventor
Emma Masteller
Hong Xiang
James Zanghi
Julie Hambleton
Robert Sikorski
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of MX2016016664A publication Critical patent/MX2016016664A/es
Publication of MX391735B publication Critical patent/MX391735B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
MX2016016664A 2014-06-23 2015-06-18 Anticuerpos que se enlazan al receptor del factor 1 estimulador de colonias (csf1r) y sus usos en el tratamiento de trastornos por cd16+ MX391735B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462015710P 2014-06-23 2014-06-23
PCT/US2015/036419 WO2015200089A1 (en) 2014-06-23 2015-06-18 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Publications (2)

Publication Number Publication Date
MX2016016664A MX2016016664A (es) 2017-03-20
MX391735B true MX391735B (es) 2025-03-21

Family

ID=53674259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016664A MX391735B (es) 2014-06-23 2015-06-18 Anticuerpos que se enlazan al receptor del factor 1 estimulador de colonias (csf1r) y sus usos en el tratamiento de trastornos por cd16+

Country Status (13)

Country Link
US (2) US10975153B2 (enExample)
EP (1) EP3157957A1 (enExample)
JP (2) JP6964410B2 (enExample)
KR (2) KR20170016501A (enExample)
CN (2) CN106795222A (enExample)
AU (1) AU2015280362B2 (enExample)
BR (1) BR112016029460A2 (enExample)
CA (1) CA2951156A1 (enExample)
EA (1) EA037561B1 (enExample)
IL (1) IL249393B (enExample)
MX (1) MX391735B (enExample)
SG (2) SG11201610672YA (enExample)
WO (1) WO2015200089A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CA3058944A1 (en) * 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN109053887B (zh) * 2018-07-18 2019-07-23 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及用途
CN108948199B (zh) * 2018-07-18 2019-06-21 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及其用途
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
US11419822B2 (en) * 2020-12-14 2022-08-23 AmMax Bio, Inc. High concentration formulations of anti-CSF1 and anti-CSF1R antibodies

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0382781B1 (en) 1987-10-23 1993-09-29 Genetics Institute, Inc. Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69329247T2 (de) 1992-06-09 2001-05-31 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Kristallisierung von m-csf
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH10218791A (ja) 1997-01-31 1998-08-18 Toagosei Co Ltd 慢性関節リウマチ治療薬
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999029345A1 (en) 1997-12-05 1999-06-17 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
BR0011197A (pt) 1999-05-07 2002-02-19 Genentech Inc Método de tratamento de uma doença autoimunológica em um mamìfero, compreendendo antagonistas que se ligam aos marcadores de superfìcie de células b e artigo de manufatura
CA2388298C (en) 1999-10-28 2013-05-14 Seyedhossein Aharinejad The use of csf-1 inhibitors
WO2001034177A2 (en) 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6773895B2 (en) 2000-09-01 2004-08-10 Boehringer Ingelheim Pharma Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US7247618B2 (en) 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
EP1423428B2 (en) 2001-06-20 2012-11-14 Fibron Ltd. Antibodies that block fgfr3 activation, methods of screening for and uses thereof
EP2246363A1 (en) 2002-11-15 2010-11-03 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
PL1678314T3 (pl) 2003-10-22 2013-02-28 Keck Graduate Inst Sposoby syntezy polipeptydów heteromultimerycznych w drożdżach, wykorzystujące strategię kojarzenia haploidalnego
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
EP1706137A2 (en) 2004-01-21 2006-10-04 Chiron Corporation M-csf muteins and uses thereof
JP2008506366A (ja) 2004-05-14 2008-03-06 レセプター バイオロジックス インコーポレイテッド 細胞表面受容体アイソフォームならびにその同定および使用方法
AU2005267062C1 (en) 2004-07-22 2013-01-17 Five Prime Therapeutics, Inc. Compositions and methods of use for MGD-CSF in disease treatment
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
AU2006207999A1 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
BRPI0618449A2 (pt) 2005-11-10 2011-08-30 Receptor Biologix Inc métodos para produção de isoformas de receptor e ligante
WO2007075933A2 (en) 2005-12-21 2007-07-05 Cell Signaling Technology, Inc. Translocation and mutant csf1r kinase in human leukemia
AU2006342119B8 (en) 2005-12-22 2013-05-09 Novartis Ag Soluble human M-CSF receptor and uses thereof
CN101534858A (zh) 2006-01-05 2009-09-16 诺华有限公司 预防和治疗癌症转移和癌症转移相关性骨丢失的方法
AU2007248493B2 (en) 2006-05-04 2010-09-30 The Rockefeller University HCV coreceptor and methods of use thereof
US7833789B2 (en) 2006-08-01 2010-11-16 Fondazione Centro San Raffaele Del Monte Tabor Monocyte cell
EP2089049A4 (en) 2006-11-17 2011-11-16 Biogen Idec Inc SYSTEMIC ADMINISTRATION OF COLONIAL STIMULATING FACTORS TO TREAT AMYLOID ASSOCIATED DISEASES
ATE494306T1 (de) 2007-02-14 2011-01-15 Vaccinex Inc Humanisierte anti-cd100-antikörper
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
WO2008150383A1 (en) 2007-05-30 2008-12-11 Albert Einstein College Of Medicine Of Yeshiva University Csf-1r mutants
SG10201500328QA (en) 2007-08-21 2015-03-30 Amgen Inc Human c-fms antigen binding proteins
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
EP2215482A2 (en) 2007-10-31 2010-08-11 Janssen Pharmaceutica N.V. Biomarker for assessing response to fms treatment
JPWO2009075344A1 (ja) 2007-12-12 2011-04-28 独立行政法人国立がん研究センター Ｍ−ｃｓｆ受容体を分子標的とするｍｌｌ白血病及びｍｏｚ白血病治療剤、およびその利用
WO2009112245A1 (en) 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
CN105218672A (zh) 2009-12-10 2016-01-06 霍夫曼-拉罗奇有限公司 优先结合人csf1r胞外域4的抗体及其用途
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
RU2617966C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
KR20200044999A (ko) * 2010-05-04 2020-04-29 파이브 프라임 테라퓨틱스, 인크. Ｃｓｆ1ｒ에 결합하는 항체들
WO2012082573A1 (en) 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
US20140288279A1 (en) 2011-10-21 2014-09-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System
US9139652B2 (en) 2011-10-21 2015-09-22 Transgene Sa Method for increasing M1 macrophages in a patient
EP2847220A1 (en) * 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
TWI713436B (zh) * 2012-08-31 2020-12-21 美商戊瑞治療有限公司 用結合群落刺激因子１受體（ｃｓｆ１ｒ）之抗體治療病狀之方法
PL3212670T3 (pl) * 2014-10-29 2021-06-14 Five Prime Therapeutics, Inc. Leczenie skojarzone nowotworów

Also Published As

Publication number Publication date
KR20170016501A (ko) 2017-02-13
SG10201811475YA (en) 2019-02-27
US10975153B2 (en) 2021-04-13
IL249393B (en) 2022-02-01
AU2015280362A1 (en) 2016-12-22
JP2017520562A (ja) 2017-07-27
US20170152320A1 (en) 2017-06-01
JP6964410B2 (ja) 2021-11-10
BR112016029460A2 (pt) 2017-10-24
SG11201610672YA (en) 2017-01-27
CN113350501A (zh) 2021-09-07
KR20230086809A (ko) 2023-06-15
EA037561B1 (ru) 2021-04-14
WO2015200089A1 (en) 2015-12-30
US20210317219A1 (en) 2021-10-14
EA201692482A1 (ru) 2017-05-31
CN106795222A (zh) 2017-05-31
CA2951156A1 (en) 2015-12-30
EP3157957A1 (en) 2017-04-26
MX2016016664A (es) 2017-03-20
JP2020169179A (ja) 2020-10-15
IL249393A0 (en) 2017-02-28
AU2015280362B2 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
DOP2017000025A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
MX2017013178A (es) Terapia de combinacion para cancer.
PH12017501521A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
MX389789B (es) Moléculas del receptor de envolvimiento quimérico.
MX2017005553A (es) Terapia de combinacion para cancer.
CL2018001384A1 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
MX2023006304A (es) Administracion de celulas t dise?adas para tratamiento de canceres en el sistema nervioso central.
MX394103B (es) Anticuerpos anti-angptl8 y usos de estos.
EA201791421A1 (ru) Антитела против csf1r для лечения pvns
PH12017500825A1 (en) Anti-cldn chimeric antigen receptors and methods of use
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX391735B (es) Anticuerpos que se enlazan al receptor del factor 1 estimulador de colonias (csf1r) y sus usos en el tratamiento de trastornos por cd16+
EA033335B1 (ru) Антитело к интерлейкину-21 и его применение для лечения аутоиммунного состояния
MX2024004377A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
BR112017011513A2 (pt) tratamento de condições oculares usando células progenitoras
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
AR103227A1 (es) Anticuerpos anti-csf1r para el tratamiento de svp
CR20190176A (es) Usos de antagonistas de il-13 para el tratamiento de dermatitis atópica
AR102952A1 (es) Tratamiento de condiciones oculares usando células progenitoras